JP4742023B2 - 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング - Google Patents

脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング Download PDF

Info

Publication number
JP4742023B2
JP4742023B2 JP2006500788A JP2006500788A JP4742023B2 JP 4742023 B2 JP4742023 B2 JP 4742023B2 JP 2006500788 A JP2006500788 A JP 2006500788A JP 2006500788 A JP2006500788 A JP 2006500788A JP 4742023 B2 JP4742023 B2 JP 4742023B2
Authority
JP
Japan
Prior art keywords
nucleic acid
sirna
androgen
double
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006500788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524038A (ja
JP2006524038A5 (enExample
Inventor
カフン シャハルヤル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gencia Corp
Original Assignee
Gencia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencia Corp filed Critical Gencia Corp
Publication of JP2006524038A publication Critical patent/JP2006524038A/ja
Publication of JP2006524038A5 publication Critical patent/JP2006524038A5/ja
Application granted granted Critical
Publication of JP4742023B2 publication Critical patent/JP4742023B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/0121—3-Beta (or 20-alpha)-hydroxysteroid dehydrogenase (1.1.1.210)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01213—3Alpha-hydroxysteroid 3-dehydrogenase (A-specific) (1.1.1.213)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/99—Oxidoreductases acting on the CH-CH group of donors (1.3) with other acceptors (1.3.99)
    • C12Y103/99005—3-Oxo-5alpha-steroid 4-dehydrogenase (acceptor) (1.3.99.5), i.e. steroid-5alpha-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06002—Steryl-sulfatase (3.1.6.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
JP2006500788A 2003-01-03 2004-01-05 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング Expired - Fee Related JP4742023B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43784203P 2003-01-03 2003-01-03
US60/437,842 2003-01-03
PCT/US2004/000128 WO2004063331A2 (en) 2003-01-03 2004-01-05 SiRNA MEDIATED POST-TRANSRIPTIONAL GENE SILENCING OF GENES INVOLVED IN ALOPECIA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010286475A Division JP2011120589A (ja) 2003-01-03 2010-12-22 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング

Publications (3)

Publication Number Publication Date
JP2006524038A JP2006524038A (ja) 2006-10-26
JP2006524038A5 JP2006524038A5 (enExample) 2007-02-15
JP4742023B2 true JP4742023B2 (ja) 2011-08-10

Family

ID=32713236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006500788A Expired - Fee Related JP4742023B2 (ja) 2003-01-03 2004-01-05 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング
JP2010286475A Pending JP2011120589A (ja) 2003-01-03 2010-12-22 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010286475A Pending JP2011120589A (ja) 2003-01-03 2010-12-22 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング

Country Status (6)

Country Link
US (1) US20070141009A1 (enExample)
EP (2) EP2462936A1 (enExample)
JP (2) JP4742023B2 (enExample)
AU (1) AU2004204068B8 (enExample)
CA (1) CA2512337A1 (enExample)
WO (1) WO2004063331A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689864A2 (en) * 2003-10-21 2006-08-16 Dyad Pharmaceutical Corporation Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
WO2005045037A2 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
US8168600B2 (en) 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
DE102005023170A1 (de) * 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
EP2023951A4 (en) * 2006-05-19 2010-01-13 Univ Rochester PROSTATEEPITHEL ANDROGEN RECEPTOR FOR THE SUPPRESSION OF PROSTATE GROWTH AND TUMORINVASION
AR055648A1 (es) * 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
NZ585327A (en) * 2007-11-26 2012-10-26 Santaris Pharma As Lna antagonists targeting the androgen receptor
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
JP5283106B2 (ja) * 2008-03-14 2013-09-04 国立大学法人 熊本大学 Ｃ型肝炎ウイルス阻害剤
WO2013009717A1 (en) * 2011-07-10 2013-01-17 Elisabet De Los Pinos Virion derived protein nanoparticles for delivering diagnostic or therapeutic agents for the treatment of skin-related diseases
EP2725103A3 (en) * 2011-11-14 2016-01-06 Silenseed Ltd Methods and compositions for treating prostate cancer
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US9655999B2 (en) 2013-03-12 2017-05-23 Carnegie Mellon University Coated vaso-occlusive device for treatment of aneurysms
JP6768253B2 (ja) * 2015-10-09 2020-10-14 井上　肇 対象者の男性型脱毛症に関する情報を取得する方法
GB201519734D0 (en) * 2015-11-09 2015-12-23 Univ Swansea Cancer therapy
KR102321426B1 (ko) * 2017-02-21 2021-11-05 올릭스 주식회사 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA
KR102473989B1 (ko) 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US5571817A (en) 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5877160A (en) * 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
US6733776B1 (en) * 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
AU695165B2 (en) * 1994-07-15 1998-08-06 City Of Hope Cleavage of 5 alpha-reductase mRNA
US5670643A (en) 1995-03-16 1997-09-23 Glaxo Wellcome Inc. Method for preparing finasteride
AU2666797A (en) * 1996-04-15 1997-11-07 Dyad Pharmaceutical Corporation Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
US20080039414A1 (en) * 2002-02-20 2008-02-14 Sima Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
JP4173667B2 (ja) * 2001-02-28 2008-10-29 北海道三井化学株式会社 アンドロゲン受容体作用阻害剤
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050170371A1 (en) * 2001-05-18 2005-08-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
JP4869498B2 (ja) * 2001-05-31 2012-02-08 丸善製薬株式会社 抗男性ホルモン剤、及び養毛化粧料、皮脂分泌抑制剤並びに前立腺肥大抑制剤
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
FR2840217B1 (fr) * 2002-06-03 2005-06-24 Oreal Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP1689864A2 (en) * 2003-10-21 2006-08-16 Dyad Pharmaceutical Corporation Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor

Also Published As

Publication number Publication date
JP2006524038A (ja) 2006-10-26
WO2004063331A9 (en) 2005-11-17
US20070141009A1 (en) 2007-06-21
EP1590430A4 (en) 2009-08-05
AU2004204068B8 (en) 2010-03-25
AU2004204068B2 (en) 2009-11-26
EP1590430A2 (en) 2005-11-02
WO2004063331A3 (en) 2007-08-09
AU2004204068A1 (en) 2004-07-29
WO2004063331A2 (en) 2004-07-29
CA2512337A1 (en) 2004-07-29
EP2462936A1 (en) 2012-06-13
JP2011120589A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
JP2011120589A (ja) 脱毛に関与する遺伝子の、ｓｉＲＮＡ転写後遺伝子サイレンシング
Li et al. MicroRNA-328 as a regulator of cardiac hypertrophy
JP6837963B2 (ja) Ｍｉｒ−２９模倣物およびその使用
CN101868251B (zh) 含有HIF-1α和HIF-2α表达抑制物质的药物
EP3301178B1 (en) The mirna-212/132 family as a therapeutic target
US12234455B2 (en) Therapeutic oligonucleotides
US20060069055A1 (en) Delivery of polynucleotides
EP3587577B1 (en) Asymmetric sirna for inhibiting expression of male pattern hair loss target gene
Xu et al. NSD2 promotes pressure overload-induced cardiac hypertrophy via activating circCmiss1/TfR1/ferroptosis signaling
KR20140038388A (ko) 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
EP3329004B1 (en) Therapeutic oligonucleotides
WO2013113032A1 (en) G protein-coupled purinergic receptor gpr17 mediates orexigenic effects of foxo1 in agrp neurons
CN108025017A (zh) MiR-19调节剂及其用途
Zhao et al. MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension–Implication for novel glaucoma therapy
US8173616B2 (en) RNA-induced translational silencing and cellular apoptosis
WO2025155574A1 (en) Modulation of akap12 signalosome
WO2024003350A1 (en) Combination therapy for melanoma
WO2021104208A1 (zh) 预防皮肤衰老与早衰的内源性小rna分子标靶及其应用
EP3212202B1 (en) Mcl-1 inhibitors for use in treating diseases caused by pathological neovascularisation
JP2022088371A (ja) 核酸オリゴマーとその用途
TW201726162A (zh) 用於治療掉髮之方法及組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110304

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110419

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110509

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140513

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees